US Edition
News from cancernetwork.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top cancernetwork.com News
FDA · United States(MedPage Today) -- The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell lung cancer, the agency announced...See the Story
FDA Approves Maintenance Combo for Small Cell Lung Cancer
80% Center coverage: 5 sources
Breast Cancer · United StatesOn Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). The FDA approval is based on the results of the EMBER-3 trial in the patient populatio…See the Story
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - Eli Lilly (NYSE:LLY)
60% Center coverage: 5 sources
BARTRadiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, muscle-invasive bladder cancer, according to results of a new phase III randomized trial.See the Story
Post-Operative Radiation Therapy Reduces Pelvic Relapse in High-Risk Bladder Cancer
100% Center coverage: 1 sources
